Investing Profile

Stephen Squinto

InvestorVC
Executive Partner at Orbimed
orbimed.comNew York, New York
Photo of Stephen Squinto, Partner at OrbiMed
Your Intro Paths to Stephen Squinto
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌

Find Stephen Squinto on

cb
Current Investing Position
OrbiMed Partner
Investment Range
$1M - $75.0M
Sweet Spot
$4.0M
Investments On Record
15
Current Fund Size
$18B

Stephen Squinto is on these Sector & Stage Rankings

Stephen Squinto's Investments On Record (8)

CompanyStageDateRound SizeTotal Raised
Enlaza Therapeutics
Series AApr 2024$100M
$160M
Co-investors: James N. Topper (Frazier Healthcare Partners), Marcos Milla (Samsara BioCapital), Jay Lichter (Avalon Ventures)
iECURE
Series ASep 2021$50M
$120M
Co-investors: Tom Woiwode (Versant Ventures)
Gennao Bio
Series AMay 2021$40M
$40M
Co-investors: Chau Khuong (OrbiMed)
Chemomab
Post Ipo EquityMar 2021$46M
$76M
Co-investors: Peter Thiel (Founders Fund), Fabian Hansen (Presight Capital)
Gemini Therapeutics
Post Ipo EquityFeb 2021$95M
Series AOct 2017$43M
SeedApr 2016$2M
$140M
Co-investors: Carl Gordon (OrbiMed), Jason Rhodes (Atlas Venture), Jean George (Advanced Technology Ventures)
Therachon
Series BAug 2018$60M
Series AJan 2017$5M
Series ASep 2015$35M
$100M
Co-investors: Tom Woiwode (Versant Ventures), Sara Nayeem (Avoro Ventures)
Arvinas
Series CApr 2018$55M
Series BOct 2015$42M
$140M
Co-investors: Tim Shannon (Canaan Partners), Colleen Cuffaro (Canaan Partners), Kush Parmar (5am Ventures), Martin Alexander Gershon (Endeavor Venture Funds), Jakob Loven (Nextech Invest), Liam Ratcliffe (Access Biotechnology), Andrew Levin (RA Capital), Daniel Wagner (Connecticut Innovations)
Audentes Therapeutics
Series COct 2015$65M
Series BDec 2014$43M
Series AJul 2013$30M
$140M
Co-investors: Kush Parmar (5am Ventures), Jonathan Silverstein (OrbiMed), Tom Woiwode (Versant Ventures), Jonathan Leff (Deerfield Management)